Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Executive Summary
Merck and Schering-Plough are pricing Zetia so that combination use with Zocor 10 mg is attractive compared to high-dose Zocor monotherapy
You may also be interested in...
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering-Plough and Merck are likely to price the Zocor/Zetia combination Vytorin on par with Pfizer's Lipitor, Merck indicated during an April 22 conference call
Combo Drug Commercial Potential May Be Lowered By D.C. Court Ruling
A Washington, D.C. federal appeals court ruling could have a significant impact on pharmaceutical companies that are eying combination therapies as growth drivers